

April 1, 2020

**CURRICULUM VITAE**  
**Rishi R. Lulla, MD MS**

Business Address: 593 Eddy Street, Multiphasic 117, Providence, Rhode Island 02903

Business Telephone Number: (401) 444-5171

Business Fax Number: (401) 444-8845

Electronic Mail Address: [rishi\\_lulla@brown.edu](mailto:rishi_lulla@brown.edu)

**EDUCATION**

Undergraduate            Boston University, 1995-1999  
Bachelor of Arts: Biology, Dean's List with Honors, magna cum laude,  
awarded early admission to Medical Doctorate program

Medical School            Boston University School of Medicine, 1999-2003

Other Degrees            Northwestern University Feinberg School of Medicine, 2008-2010  
Master of Science in Clinical Investigation

**POSTGRADUATE TRAINING**

Residency                Northwestern University Feinberg School of Medicine  
240 E Huron St #1-200, Chicago, Illinois 60611  
Pediatrics, 2003-2006  
Chief Resident in Pediatrics, Children's Memorial Hospital 2006-2007

Fellowship                Northwestern University Feinberg School of Medicine  
240 E Huron St #1-200, Chicago, Illinois 60611  
Pediatric Hematology, Oncology and Stem Cell Transplant, 2007-2010  
Advanced Fellowship, Pediatric Neuro-Oncology, 2010-2011

**POSTGRADUATE HONORS AND AWARDS**

Resident Teacher of the Year, Children's Memorial Hospital Teaching Award, 2005

Fellow of the Year, Children's Memorial Hospital Teaching Award, 2008

Outstanding Faculty Teaching Award, Northwestern University Feinberg School of  
Medicine Department of Pediatrics, 2013, 2014

Hero Award, for Outstanding Dedication and Contributions to Pediatric Neuro-Oncology,  
Pediatric Brain Tumor Foundation, 2015

Chicago's Top Cancer Doctors, Chicago Magazine, 2017

## PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Illinois State Physician License #036-114875 (C.S. 336076182), 2005

Board Certified in General Pediatrics, American Board of Pediatrics, 2006

Board Certified, Pediatric Hematology-Oncology, American Board of Pediatrics, 2011

Rhode Island State Medical License #16312, 2018

## ACADEMIC APPOINTMENTS

Instructor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2006-2008

Assistant Professor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2011-2017

Associate Professor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 2017- 2018

Alan G. Hassenfeld Associate Professor of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, 2018 -

## HOSPITAL APPOINTMENTS

Attending Physician, General Academic Pediatrics, Children's Memorial Hospital, Chicago, Illinois, 2006-2007

Attending Physician, Emergency Medicine (Urgent Care), Children's Memorial Hospital, Chicago, Illinois, 2006-2011

Attending Physician, Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, 2011- 2018

Attending Physician, Pediatric Hematology-Oncology, Central DuPage Hospital and Northwestern Medicine Proton Center, Warrenville, Illinois, 2012- 2018

Attending Physician, Pediatric Hematology-Oncology, Women and Infant's Hospital Providence, Rhode Island 2018 -

Division Director, Pediatric Hematology-Oncology  
Hasbro Children's Hospital/Rhode Island Hospital, Providence, Rhode Island 2018 -

## OTHER APPOINTMENTS

Pediatric Brain Tumor Consortium  
Biology Committee, 2012- 2018  
Toxicity Monitoring Committee, 2014-2018  
Data Safety Monitoring Board, 2018 -

Bear Necessities Pediatric Cancer Foundation  
Scientific Advisory Board, 2013-

Children's Brain Tumor Tissue Consortium  
Scientific Committee, 2013- 2018  
Site Principal Investigator and Executive Committee, 2015- 2018  
Executive Board Chair, 2016- 2018

Pacific Pediatric Neuro-Oncology Consortium  
Site Principal Investigator, 2017- 2018

Children's Oncology Group  
Central Nervous System Tumors Committee, 2017 –

Brown University Research Oncology Group  
Co-Director, Central Nervous System Tumor Committee  
Co-Director, Pediatric Committee  
Site Principal Investigator, 2019 –

Brown University, Pediatric Hematology-Oncology Fellowship  
Program Director, 2019 –

Ad Hoc Reviewer  
Journal of Pediatric Hematology/Oncology 2012 -  
Journal of Neuro-Oncology 2012 -  
Child's Nervous System 2012 -  
Cancer Genetics 2013 - 2016  
Journal of Pediatric Neurosurgery 2013 -  
Journal of Child Neurology 2013 -  
PLOS One 2013 -  
Neuro-Oncology 2015 –  
Frontiers in Oncology 2018 –

Editorial Board  
Cancer Biology and Therapy 2019 –

#### HOSPITAL COMMITTEES

Pediatric Residency Program, Candidate Interviewer and Faculty Advisor, Ann & Robert  
H. Lurie Children's Hospital of Chicago 2011 - 2018

Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant Educational Conferences and Morbidity and Mortality Conference, Ann & Robert H. Lurie Children's Hospital of Chicago, Physician Leader, 2012 - 2018

Provider Advisory Committee, Ann & Robert H. Lurie Children's Hospital of Chicago Appointed Member, 2014 - 2018

Hematology-Oncology CLABSI Prevention Taskforce Ann & Robert H. Lurie Children's Hospital of Chicago, Member, 2016 - 2018

Institutional Review Board, Ann & Robert H. Lurie Children's Hospital of Chicago, Appointed Member, 2016 - 2018

Ambulatory Leadership Steering Committee, Ann & Robert H. Lurie Children's Hospital of Chicago, Appointed Member, 2016 - 2018

Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant Epic Beacon Implementation Team, Ann & Robert H. Lurie Children's Hospital of Chicago Physician Leader, 2017 - 2018

Lifespan Cancer Institute, Cancer Clinical and Research Council, Rhode Island Hospital/Hasbro Children's Hospital, Co-Chair, 2018 –

Lifespan Cancer Institute, Cancer Institute Operations Committee, Rhode Island Hospital/Hasbro Children's Hospital, Member, 2018 –

Lifespan Cancer Institute, Cancer Oversight Committee, Rhode Island Hospital/Hasbro Children's Hospital, Member, 2018 -

Proton Center Working Group, Rhode Island Hospital/Hasbro Children's Hospital, Member, 2018 –

Cell Therapy Working Group, Rhode Island Hospital/Hasbro Children's Hospital, Member, 2018 –

#### UNIVERSITY COMMITTEES

Lurie Cancer Center Scientific Review Committee, Northwestern University Feinberg School of Medicine, 2011-2018

Lurie Cancer Center Disease Team Charter, Co-Leader Pediatric Oncology, Northwestern University Feinberg School of Medicine, 2015- 2018

Brown University Research Oncology Group, The Warren Alpert Medical School of Brown University, Executive Committee Member, 2019 –

Faculty Search Committee, Pediatric Infectious Disease Division Director, The Warren Alpert Medical School of Brown University, Member, 2018 –

Faculty Search Committee, Pediatric Gastroenterology Division Director, The Warren Alpert Medical School of Brown University, Member, 2019 – 2020

Faculty Search Committee, Department of Pathology and Laboratory Medicine Joint Program in Cancer Biology, The Warren Alpert Medical School of Brown University, Member, 2019 –

Chair, Faculty Search Committee, Adolescent Medicine Division Director, The Warren Alpert Medical School of Brown University, Member, 2020 -

Central Nervous System Translational Disease Research Group, Department of Pathology and Laboratory Medicine Joint Program in Cancer Biology, The Warren Alpert Medical School of Brown University, Member, 2019 -

Sarcoma Translational Disease Research Group, Department of Pathology and Laboratory Medicine Joint Program in Cancer Biology, The Warren Alpert Medical School of Brown University, Member, 2019 –

Cancer Therapeutics Research Group, Department of Pathology and Laboratory Medicine Joint Program in Cancer Biology, The Warren Alpert Medical School of Brown University, Member 2019 –

#### MEMBERSHIP IN SOCIETIES

American Society of Pediatric Hematology Oncology, Member, 2007-

American Society of Clinical Oncology, Member, 2007-

Children's Oncology Group, Member, 2007-

Society of Neuro-Oncology, Member, 2009-

Association of Pediatric Program Directors, 2019 –

#### PUBLICATIONS LIST

##### ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Patel D, Piotrowski ZH, **Lulla RR**. Multiple births among adolescent women in Illinois. *J Reprod Med*. 1997 Dec;42(12):779-84.
2. Kondo A, Goldman S, **Lulla RR**, Mania-Farnell B, Vanin EF, Sredini ST, Soares MB and Tomita T. Longitudinal assessment of regional directed delivery in a rodent malignant glioma model. *J Neurosurg Pediatr* 2009 Dec; 4(6):592-8.

3. **Lulla RR**, Thompson AT and Liem RI. Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency anemia in pediatric sickle cell disease. *Pediatr Blood Cancer* 2010 Jul 15; 55(1):141-4.
4. **Lulla RR**, Allen GA, Zakarija A, and Green, D. Transplacental transfer of postpartum inhibitors to factor VIII. *Haemophilia* 2010 Jan; 16(1):14-7.
5. **Lulla RR**, Costa FF, Bischof JM, Chou PM, Bonaldo MF, Vanin EF, Soares, MB. Identification of Differentially Expressed microRNAs in Osteosarcoma. *Sarcoma* 2011 Article ID 732690, 6 pages.
6. Costa FF, Bischof JM, Vanin EF, **Lulla RR**, Wang M, Sredni ST, Rajaram V, Bonaldo MF, Wang D, Goldman S, Tomita T, Soares MB. (July, 2011). Identification of microRNAs as potential prognostic markers in ependymoma. *PLoS ONE* 6(10): e25114.
7. Rao VK, Haridas A, Nguyen TT, **Lulla RR**, Wainwright MS, Goldstein JL. Symptomatic Cerebral Vasospasm Following Resection of a Medulloblastoma in a Child. *Neurocrit Care*. 2013 Feb;18(1):84-8
8. Eckerdt F, Beauchamp E, Bell J, Iqbal A, Su B, Fukunaga R, **Lulla R**, Goldman S, Plataniias LC. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. *Oncotarget*. 2014 Sep 30;5(18):8442-51.
9. Merino DM, Shlien A, Villani A, Pienkowska M, Mack S, Ramaswamy V, Shih D, Tatevossian R, Novokmet A, Choufani S, Dvir R, Ben-Arush M, Harris BT, Hwang EI, **Lulla R**, Pfister SM, Achatz MI, Jabado N, Finlay JL, Weksberg R, Bouffet E, Hawkins C, Taylor MD, Tabori U, Ellison DW, Gilbertson RJ, Malkin D. Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clin Cancer Res*. 2015 Jan 1;21(1):184-92
10. Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, **Lulla R**, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. *J Neurooncol*. 2015 Jan;121(1):217-24.
11. Brower JV, Gans S, Hartsell WF, Goldman S, Fangusaro JR, Patel N, **Lulla RR**, Smiley NP, Chang JH, Gondi V. Proton therapy and helical tomotherapy result in reduced dose deposition to the pancreas in the setting of cranio-spinal irradiation for medulloblastoma: implications for reduced risk of diabetes mellitus in long-term survivors. *Acta Oncol*. 2015 Apr;54(4):563-6
12. Malchenko S, Sredni ST, Hashimoto H, Kasai A, Nagayasu K, Xie J, Margaryan NV, Seiriki K, **Lulla RR**, Seftor RE, Pachman LM, Meltzer HY, Hendrix MJ, Soares MB. A mouse model of human primitive neuroectodermal tumors resulting from microenvironmentally-

driven malignant transformation of orthotopically transplanted radial glial cells. *PLoS One*. 2015 Mar 31;10(3):e0121707

13. Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, Ra YS, Ho KC, Chan TS, Sin-Chan P, Dunham CP, Yip S, Ng HK, Lu JQ, Albrecht S, Pimentel J, Chan JA, Somers GR, Zielenska M, Faria CC, Roque L, Baskin B, Birks D, Foreman N, Strother D, Klekner A, Garami M, Hauser P, Hortobágyi T, Bognár L, Wilson B, Hukin J, Carret AS, Van Meter TE, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheineman K, Johnston D, Michaud J, Zelcer S, Hammond R, Ramsay DA, Fleming AJ, **Lulla RR**, Fangusaro JR, Sirachainan N, Larbcharoensub N, Hongeng S, Barakzai MA, Montpetit A, Stephens D, Grundy RG, Schüller U, Nicolaides T, Tihan T, Phillips J, Taylor MD, Rutka JT, Dirks P, Bader GD, Warmuth-Metz M, Rutkowski S, Pietsch T, Judkins AR, Jabado N, Bouffet E, Huang A. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. *Lancet Oncol*. 2015 May;16(5):569-82.
14. Aw-Zoretic J, Wadhvani NR, **Lulla RR**, Ryan ME. Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report. *Childs Nerv Syst*. 2015 Sep;31(9):1625-9
15. **Lulla RR**, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. *Neuro Oncol*. 2016 Mar 28
16. Iqbal A, Eckerdt F, Bell J, Nakano I, Giles FJ, Cheng SY, **Lulla RR**, Goldman S, Platanias LC. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110 $\alpha$  inhibition. *Oncotarget* 2016 Apr 21.
17. Hashizume R, Zhang A, Mueller S, Prados MD, **Lulla RR**, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. *Neuro-Oncol*. 2016 Jul 1
18. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, ... **Lulla RR**, ... Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*. 2016 Dec 12.
19. Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendelman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, **Lulla RR**, Saratsis AM, Kellerher NL, James CJ, Shilatifard A. Heterotypic nucleosomes and PRC2 drive DIPG oncogenesis. *Nature Medicine* 2017 Apr 23.

20. Huang TY, Piunti A, **Lulla RR**, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. *Acta Neuropathol Commun*. 2017 Apr 17.
21. Finelt N, **Lulla RR**, Melin-Aldana H, Ruth JS, Lin FY, Su JM, Pourciau CY, Hunt RD, Kenner-Bell BM. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib. *Pediatr Dermatol*. 2017 May.
22. Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, **Lulla R**, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. *Transl Res*. 2017 Oct.
23. Choi DK, Pillay-Smiley N, Marzec S, Wadhwani NR, DiPatri AJ, Tomita T, **Lulla RR**. Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. *J Pediatr Hematol Oncol*. 2018 Feb 2. doi: 10.109
24. Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K, **Lulla RR**, Goldman S, Nazarian J, Rajaram V, Fangusaro J, Gopalakrishnan V. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. *Oncotarget*. 2017 Dec 28;9(4):5233-5250. doi: 10.18632/oncotarget.23750. eCollection 2018 Jan 12.
25. Huang T, Garcia R, Qi J, **Lulla R**, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. *Oncotarget*. 2018 Dec 14;9(98):37112-37124
26. Dobson THW, Tao RH, Swaminathan J, Maegawa S, Shaik S, Bravo-Alegria J, Sharma A, Kennis B, Yang Y, Callegari K, Haltom AR, Taylor P, Kogiso M, Qi L, Khatua S, Goldman S, **Lulla RR**, Fangusaro J, MacDonald TJ, Li XN, Hawkins C, Rajaram V, Gopalakrishnan V. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. *Sci Signal*. 2019 Jan 22;12(565).
27. Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, Polanco MLS, Guzik BW, Aguilar-Cordova E, Diaz-Montero CM, DiPatri AJ, Tomita T, Lulla R, Greenspan L, Aguilar LK, Goldman S. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. *Neuro Oncol*. 2019 Mar 18;21(4):537-546.

28. Gross JP, Powell S, Zelko F, Hartsell W, Goldman S, Fangusaro J, **Lulla RR**, Smiley NP, Chang JH, Gondi V. Improved neuropsychological outcomes following proton therapy relative to x-ray therapy for pediatric brain tumor patients. *Neuro Oncol*. 2019 Apr 17.
29. Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y, Lamano JB, Carcaboso AM, Tian X, Seluanov A, Gorbunova V, Laurie KL, Kondo A, Wadhwani NR, **Lulla R**, Goldman S, Venneti S, Becher OJ, Zou L, Shilatifard A, Hashizume R. Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine. *Glioma. Clin Cancer Res*. 2019 Jun 21
30. Ijaz H, Koptyra M, Gaonkar KS, Rokita JL, Baubet VP, Tauhid L, Zhu Y, Brown M, Lopez G, Zhang B, Diskin SJ, Vaksman Z; Children's Brain Tumor Tissue Consortium, Mason JL, Appert E, Lilly J, **Lulla R**, De Raedt T, Heath AP, Felmeister A, Raman P, Nazarian J, Santi MR, Storm PB, Resnick A, Waanders AJ, Cole KA. Pediatric High-Grade Glioma Resources From the Children's Brain Tumor Tissue Consortium. *Neuro Oncol*. 2020 Jan 11;22(1):163-165

#### OTHER PEER-REVIEWED PUBLICATIONS

1. **Lulla RR**, Foy AB, DiPatri AJ and Fangusaro J. Emergencies in children and young adults with central nervous system tumors. *Clinical Pediatric Emergency Medicine* September 2011.
2. **Lulla RR**, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. *Sci Adv*. 2016 Mar 18;2(3): e1501354.
3. Ladomersky E, Gene M, Zhai L, Galina G, Lauing KL, **Lulla RR**, Fangusaro J, Lenzen A, Kumthekar PK, Raizer JJ, Binder DC, James CD, Wainwright DA. Improving Vaccine Efficacy Against Malignant Glioma. *Oncoimmunology* . 2016 Jun 10

#### BOOKS AND BOOK CHAPTERS

1. **Lulla RR** and Fangusaro J. "An overview of pediatric high-grade gliomas and diffuse intrinsic pontine glioma." in *Tumors of the Central Nervous System*. Springer Publishing 2013
2. Sredni ST and **Lulla RR**. "Atypical teratoid rhabdoid tumors." in *Tumors of the Central Nervous System* Springer Publishing 2013

#### ABSTRACTS

1. **Lulla RR**, Costa FF, Hamm CA, Fangusaro J, Sredni ST, Vanin EF, Goldman S, Soares MB. Circulating microRNAs in plasma and cerebrospinal fluid of pediatric patients with central nervous system tumors. Society of Neuro-Oncology Pediatric Translational Meeting, New Orleans, May 2011.

2. **Lulla RR**, Echevarria M, Alden T, DiPatri AJ Tomita, T, Goldman S and Fangusaro J. “Primary Thalamic Tumors of Astrocytic Origin: A 20-year Experience at Children's Memorial Hospital.” *Neuro Oncol* (2012) 14 (suppl 1): i56-i68.
3. Fernandez KS, Antony R, **Lulla RR**, Flores M, Benavides VC, Mitchell C. Brainstem Glioma Responsive to Pegvisomant and Chemotherapy in a Patient with NF-1 Related Optic Pathway Glioma and Growth Hormone Excess. *Neuro Oncol* (2012) 14 (suppl 1): i69-i81.
4. Rubens J, **Lulla RR**, Lai JS, Fangusaro J. A Pilot Study Evaluation Long-Term Impact of Posterior Fossa Syndrome on Quality of Life in Survivors of Childhood Medulloblastoma. *Neuro Oncol* (2012) 14 (suppl 1): i111-i115.
5. Goldman S, Fangusaro J, **Lulla RR**, Chi S, Manley P, Robison N, Kroon HA, Kieran M. “Phase I Individual Dose Titration Trial of the Human Corticotrophin Releasing Factor (HCRF), Corticorelin Acetate Injection (Xerecept) in Pediatric Patients with Peritumoral Edema of the Brain” *Neuro Oncol* (2012) 14 (suppl 1): i16-i21.
6. Loret De Mola R, Laskowski J, Fangusaro J, Costa FF, Vanin EF, Goldman S, Soares MB, **Lulla RR**. Clinical and Biological Characteristics of Clear Cell Ependymoma. *Neuro Oncol* (2013) 15 (suppl 1): i1-i51.
7. **Lulla RR**, Rao VK, Haridas A, Ryan M, Goldstein JL, Wainwright MS, Tomita T. Symptomatic Cerebral Vasospasm Following Resection of Childhood Medulloblastoma. *Neuro Oncol* (2012) 14 (suppl 1): i116-i120.
8. Datar V, Bocharé S, Singh A, Khatua S, Fangusaro J, Goldman S, **Lulla RR**, Rajaram V, Gopalakrishnan V. Study of Histone Methyl Transferase G9a Inhibition in ATRT and Medulloblastoma. *Neuro Oncol* (2013) 15 (suppl 1): i1-i51.
9. **Lulla RR**, Laskowski J, Fangusaro J, DiPatri AJ, Alden T, Vanin EF, Tomita T, Goldman S, Soares MB. Longitudinal assessment of circulating microRNAs biomarkers in pediatric central nervous system tumors. *Neuro Oncol* (2013) 15 (suppl 1): i1-i51.
10. **Lulla RR**, Laskowski J, Gireud M, Fangusaro J, Goldman S, Gopalakrishnan V. Expression of miR-203 is associated with an aggressive phenotype in pediatric medulloblastoma. *Neuro Oncol* (2013) 15 (suppl 1): i1-i51.
11. Kumthekar P, Singh S, Pillay Smiley N, **Lulla RR**. Widespread Systemic Metastases from Medulloblastoma Without Evidence of Active CNS Involvement: A Case Series. *Neuro Oncol* (2014) 16(suppl 5): v68.
12. **Lulla RR**, Laskowski J, Goldman S, Gopalakrishnan V, Fangusaro J. MicroRNA Profiling Reveals Two Subgroups of Diffuse Intrinsic Pontine Glioma. *Neuro Oncol* (2014) 16(suppl 1): i40-i59.
13. **Lulla RR**, Goldman S, Beattie C Pollack IF, Fisher PG, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors: A Pediatric Brain Tumor Consortium Study. *Neuro Oncol* (2014) 16(suppl 1):i10-i13.
14. Dobson T, Busschers E, Taylor H, Hatcher R, Fangusaro J, **Lulla RR**, Goldman S, Rajaram V, Das C, Gopalakrishnan V. Generation of a Novel Genetic Engineered Mouse Model of Medulloblastoma. *Neuro Oncol* (2014) 16(suppl 1):i137-i145.
15. Goldman S, Fangusaro J, **Lulla RR**, Chi S, Manley P, Robison N, Kroon HA, Kieran M. Phase I Individual Dose Titration Trial of the Human Corticotrophin Releaseing Factor (HCRF), Corticorelin Acetate Injection (Xerecept) in Pediatric Patients with Peritumoral Edema of the Brain. *Neuro Oncol* (2014) 16 (suppl 3):iii23

16. **Lulla RR**, Laskowski J, Fangusaro J, DiPatri AJ, Alden T, Vanin EF, Tomita T, Goldman S, Soares MB. Longitudinal assessment of circulating microRNAs identified promising biomarkers in pediatric central nervous system tumors. *Neuro Oncol* (2014) 16(suppl 1):i137-i145.
17. **Lulla RR**, Laskowski J, Bi Y, Pillay Smiley N, Fangusaro J, Goldman S, Gopalakrishnan V. MicroRNA Expression Patterns in Tissue and Cerebrospinal Fluid Aid in the Molecular Classification of Pediatric Medulloblastoma. *Neuro-Oncol* (2015) 17(suppl 3):iii26-iii27.
18. **Lulla RR**, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G, Wu S, Onar A, Boyett JM, Fouladi M. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. *J Clin Oncol* 33, 2015 (suppl; abstr 10059).
19. Dobson T, Tao RH, Shavali D, Taylor P, Hatcher R, Buscchers E, Khatua S, Goldman S, **Lulla RR**, Rajaram V, MacDonald T, Fangusaro J, Gopalakrishnan V. Dissecting the role of Epigenetic Modulators in Shh-Drive Medulloblastoma” *Neuro Oncol* (2015) 17 (suppl3): iii26.
20. Hatcher R, Das C, Fangusaro J, Rajaram V, **Lulla RR**, Goldman S, Khatua S, Sbardella G, Gopalakrishnan V. Study of Epigenetic Dysregulation of a Novel Deubiquitinase in Medulloblastoma. *Neuro Oncol* (2015) 17 (suppl 3): iii8.
21. Ma Q, Mu L, Saratsis A, **Lulla RR**, Fangusaro J, Goldman S, James CD, Hashizume R. Histone Demethylase Inhibition in Combination with Radiation for Diffuse Intrinsic Pontine Gliomas. *Neuro Oncol* (2015) 17(suppl 5):v180-v181.
22. Qi J, Wadhvani N, Xi G, **Lulla RR**, Hashizume R, Tomita T, James CD, Saratsis A. In Vitro analysis of Tenascin-C Expression in Pediatric Brainstem Glioma. Oral Presentation: 84<sup>th</sup> Annual Meeting of the American Association of Neurological Surgeons, Chicago, IL May 2, 2016.
23. Lauing KL, **Lulla RR**, Hashizume R, Wainwright DA. Immunosuppressive IDO1 and TDO are expressed in pediatric central nervous system tumors. International Society of Pediatric Neuro-Oncology, Liverpool, England, June 2016
24. Clymer JR, Eckerdt F, Bell, JB, **Lulla RR**, Goldman S, Plataniias LC. Dual targeting of PI3K and mTOR signaling in medulloblastoma. International Society of Pediatric Neuro-Oncology, Liverpool, England, June 2016
25. Lauing KL, **Lulla RR**, Hashizume R, Wainwright DA. “Characterizing IDO1 and its therapeutic potential in human pediatric brain cancer”. Society of Neuro-Oncology, Pediatric Meeting, New York City June 2017
26. Felmeister A, **Lulla RR**, Waanders AJ, Raman P, Santi M, Lily J, Mason J, Resnick AC on behalf of the Children’s Brain Tumor Tissue Consortium. “The Children’s Brain Tumor Tissue Consortium (CBTTC) Infrastructure Facilitates Collaborative Research in Pediatric Central Nervous System Tumors” Society of Neuro-Oncology, Pediatric Meeting, New York City June 2017
27. Pratt D, Nataraj S, Banda A, Quezado M, Vats P, Koschmann C, Mody R, Chinnaiyan R, **Lulla RR**, Saratsis A, Venneti, S. “ A Meta-Analysis of H3K27M Mutations in Gliomas Demonstrates Differential Location-Dependent Prognostic Outcomes” United States and Canadian Academy of Pathology Meeting Vancouver, Canada March 2018.
28. Saratsis A, Piunti A, Huang A, Bartom E, Ozark P, Marshall S, Morgan M, Qi J, Hashizume R, **Lulla RR**, James CD, Shilatifard A. “Diffuse Intrinsic Pontine Glioma (DIPG)

- Sequencing Reveals Epigenetic Dysregulation of Gene Expression and BET Inhibition as a Novel Therapeutic Strategy” AANS Meeting, New Orleans, April 2018.
29. Borsuk R, Zhou L, **Lulla RR**, El-Deiry W “Novel imipridone combination therapies targeting oncohistone H3K27M mutant diffuse midline glioma (DMG)” AACR Meeting, San Diego, April 2020
  30. Robyn Borsuk, Lanlan Zhou, Yiqun Zhang, Varun Prabhu, Joshua Allen, Wolfgang Oster, Nikos Tapinos, Rishi R. Lulla, Wafik S. El-Deiry. " Preclinical evaluation of imipridone-based combination therapies in pediatric H3K27M mutant diffuse intrinsic pontine glioma (DIPG)” International Society of Pediatric Neuro-Oncology, 2020
  31. Rishi R. Lulla, Konstantina Svokos, Kristine Pelton, Douglas Anthony, Mehdi Touat, Keith L. Ligon. “Sustained response to crizotinib monotherapy in an infant with GOPC-ROS1 fused congenital hemispheric glioma" International Society of Pediatric Neuro-Oncology, 2020
  32. Sabine Mueller, Jared M. Taitt<sup>\*,2</sup>, Javier E. Villanueva-Meyers<sup>5</sup>, Erin R. Bonner<sup>6</sup>, Takahide Nejo<sup>2</sup>, Rishi R. Lulla<sup>7</sup>, Stewart Goldman<sup>8</sup>, Anu Banerjee<sup>2,3</sup>, Susan N. Chi<sup>9</sup>, Nicholas S. Whipple<sup>10</sup>, John R. Crawford<sup>11</sup>, Karen Gauvain<sup>12</sup>, Kellie J. Nazemi<sup>13</sup>, Payal B. Watchmaker<sup>2</sup>, Kaori Okada<sup>2</sup>, Andres M. Salazar<sup>14</sup>, Ryan D. Gilbert<sup>2</sup>, Javad Nazarian<sup>4,6</sup>, Annette M. Molinaro<sup>2</sup>, Lisa H. Butterfield<sup>15,16</sup>, Michael D. Prados<sup>2,3</sup>, and Hideho Okada<sup>2,15</sup>. Immune profiles are associated with outcomes in H3.3K27M+ patients with diffuse midline glioma receiving H3.3K27M peptide vaccine combined with poly-ICLC: a PNOC report. International Society of Pediatric Neuro-Oncology, 2020

## INVITED PRESENTATIONS

### Local

1. “Pediatric Brain Tumors: Updates in Treatment and Care” American Brain Tumor Association Patient and Family Conference, July 2011 and July 2012
2. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Ann & Robert H. Lurie Children’s Hospital of Chicago, Pediatric Grand Rounds, Chicago, Illinois October 2012.
3. “Pediatric Central Nervous System Tumors: Updates in Treatment and Care” Northwestern University Affiliated Transplant Centers Meeting, Chicago, Illinois June 2012
4. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Department of Neurological Surgery, Grand Rounds, Northwestern University Feinberg School of Medicine, Chicago, Illinois January 2014.
5. “Case Studies and Deliberation in the Pediatric Oncology Clinic” Oncofertility Conference, Northwestern University, September 2014.
6. “Contemporary Management of Adults with Pediatric Central Nervous System Tumors” Northwestern Brain Tumor Institute Symposium, Chicago, Illinois, March 2015.
7. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Combined Department of Pediatric Grand Rounds, Rush University School of Medicine and Cook County Hospital, Chicago, Illinois, December 2015.
8. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Lurie Cancer Center Grand Rounds, Northwestern University Feinberg School of Medicine, January 2016

9. “Next Generation Sequencing Informs Treatment in Pediatric Central Nervous System Tumors: Implications for Research and Clinical Care” Pediatric Brain Tumor Foundation Meet the Experts Conference, August 2016
10. “Biobank to Bedside: Translational Therapeutics for Pediatric Central Nervous System Tumors”, Pediatric Grand Rounds, The Warren Alpert School of Medicine at Brown University, April 2019.
11. “Biobank to Bedside: Translational Therapeutics for Pediatric Central Nervous System Tumors”, Department of Pathology and Laboratory Medicine Joint Program in Cancer Biology, The Warren Alpert Medical School of Brown University, Cancer Therapeutics Group Meeting, July 2019.

#### Regional, National and International

1. “Targeted Therapies for Pediatric Central Nervous System Tumors” Southern Illinois University, Pediatric Grand Rounds, Springfield, Illinois. September 2011.
2. “MicroRNAs as Biomarkers in Pediatric Central Nervous System Tumors”, World Biotechnology Conference, Boston, Massachusetts, June 2013.
3. “Linking Molecular Biology to Novel Treatments in Pediatric Central Nervous System Tumors” Department of Pediatric Grand Rounds, University of Texas MD Anderson Cancer Center, May 2014.
4. “Common Adverse Events in Patients with Central Nervous System Tumors: A Coding Primer” Pediatric Brain Tumor Consortium Annual Meeting, Atlanta Georgia, March 2015.
5. “MicroRNAs as Biomarkers in Pediatric Central Nervous System Tumors” Children’s Brain Tumor Tissue Consortium Meeting, Philadelphia, Pennsylvania, April 2015.
6. “Immunosuppressive IDO1 and TDO in pediatric central nervous system tumors” Children’s Brain Tumor Tissue Consortium, New Orleans, Louisiana, May 2016.
7. “Immunosuppressive IDO1 and TDO in pediatric central nervous system tumors” Children’s Brain Tumor Tissue Consortium, Washington DC, May 2017.
8. “Lenalidomide and Radiation Therapy for Children with Malignant Glioma” Gliomatosis Cerebri International Conference, Bethesda Maryland, June 2017
9. “Precision Medicine Studies for Pediatric Central Nervous System Tumors” Barrow Neurological Institute at Phoenix Children's Hospital, November 2017.
10. “Precision Medicine Studies for Pediatric Central Nervous System Tumors” Hudson Institute of Medical Research Pediatric CNS Cancer Research Symposium, Melbourne Australia, Invited February 2018

#### GRANTS

##### Fellowship Training Awards

1. Coleman Foundation Fellowship in Hematology, Oncology and Stem Cell Transplant, 2007-2010
2. Gus Foundation Fellowship in Pediatric Neuro-Oncology, 2010-2011

##### Foundation Research Grants

1. A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers Hyundai Hope on Wheels Research Grant (\$20,000), Principal Investigator, 2011
2. Longitudinal profiling of microRNA expression in patients with CNS tumors St. Baldrick's Foundation Research Grant (\$100,000), Principal Investigator, 2012
3. Longitudinal profiling of microRNA expression in patients with CNS tumors Bear Necessities and Flashes of Hope (\$80,000), Principal Investigator, 2012
4. Children's Brain Tumor Tissue Consortium (CBTTC) Registry and Repository Children's Brain Tumor Foundation (\$75,000/year), Co-Investigator (PI: Goldman), 2014
5. RNAi-based spherical nucleic acid and nanoconjugates for the treatment of pediatric high-grade glioma, John McNicholas Pediatric Brain Tumor Foundation (\$200,000), Co-Principal Investigator, 2015
6. Children's Brain Tumor Tissue Consortium (CBTTC) Registry and Repository (\$90,000/year), Principal Investigator, 2015-
7. Modifying the Future: Epigenetic Treatment of Pediatric Brain and Spinal Cord Tumors John McNicholas Pediatric Brain Tumor Foundation (\$1,500,000/3 years), Principal Investigator, 2016-
8. Epigenetic Targeted Therapy for Pediatric Malignant Glioma, Pediatric Cancer Research Foundation (\$100,000/ 2 years), Co-Principal Investigator, 2017
9. IDO1 as a Therapeutic Target for Pediatric Malignant Glioma, Curing Kids Cancer Foundation (\$50,000), Co-Principal Investigator, 2017

#### Government Sponsored Clinical Trial Research

- 2011 – 2018 Pediatric Brain Tumor Consortium U01CA81457, Site Co-Investigator (Site Principal Investigator: Goldman)
- 2011 – 2018 Children's Oncology Group, U10CA098543, Site Co-Investigator (Site Principal Investigator: Walterhouse)
- 2011 – 2018 Children's Oncology Group Phase I Consortium, UM1CA097452 Site Co-Investigator (Site Principal Investigator: Goldman)
- 2014 - 2015 Department of Defense, USAMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), Site Co-Investigator, Site Principal Investigator: Goldman

2018 – Children’s Oncology Group, U10CA098543, Site Co-Investigator (Site Principal Investigator: Welch)

ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG), Children’s Oncology Group, **Study Principal Investigator**

#### Industry Sponsored Clinical Trial Research

2012 A Phase I Study of AdV-tk + Prodrug Therapy in Combination with Radiation Therapy for Pediatric Brain Tumors

Sponsor: Advantagene, Inc., Site Co-Investigator, Site Principal Investigator: Goldman

2013 A Phase III, multi-center, open label, randomized controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma

Sponsor: Novartis, Inc., Site Co-Investigator, Site Principal Investigator: Goldman

2013 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab Children with Solid Tumors

Sponsor: Amgen Inc., Site Co-Investigator, Site Principal Investigator: Fangusaro

2014 Open-label, phase 2 study of bevacizumab in children and young adults with neurofibromatosis 2 and progressive vestibular schwannomas that are poor candidates for standard treatment with surgery or radiation

Sponsor: USMRMC, Office of the Congressionally Directed Medical Research Programs (CDMRP), Department of Defense (DOD) and Genentech, Site Co-Investigator, Site Principal Investigator: Goldman

2014 Ted12689: A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System

Sponsor: Sanofi Inc., Site Co-Investigator, Site Principal Investigator: Goldman

2016 - 2018 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Sponsor: Merck & Co, Site Co-Investigator, Site Principal Investigator: Goldman

2016 – 2018 Pacific Pediatric Neuro-Oncology Consortium, Site Co-Principal Investigator

2016 – 2018 A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients with Newly Diagnosed Intracranial Resectable High Grade Glioma (Arm A) and Recurrent Resectable Intracranial High Grade Glioma and Recurrent Resectable Ependymoma (Arm B)

Sponsor: Agenus Inc., Site Co-Investigator, Principal Investigator: Fangusaro

2017 – 2018 Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies

CheckMate908: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 908

Sponsor: Bristol-Myers Squibb, Co-Investigator, Principal Investigator: Goldman

2017 – 2018 A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy For Children and Young Adults with Recurrent or Progressive Primary Brain Tumors

Sponsor: Celgene Corporation., Site Co-Investigator, Principal Investigator: Fangusaro

2017 – 2018 A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Sponsor: Ziopharm Oncology, Site Co-Investigator, Principal Investigator: Goldman

2017 – 2018 NEXT17C03: Newly Diagnosed Children (Less Than 10 Years Old) with Medulloblastoma and Other Central Nervous System Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue (Head Start IV)

Sponsor: NEXT Consortium, Site Co-Investigator, Principal Investigator: Pillay-Smiley

#### UNIVERSITY TEACHING, ADVISING and MENTORING ROLES

## Didactic Teaching

Science in Medicine: Pediatric Cancer, 2013-2018

Annual lecture for Northwestern University Feinberg School of Medicine M2 students

Integrated Medical Sciences II, Brain Sciences: Clinical Neuro-Oncology

Annual lecture for the Warren Alpert Medical School of Brown University, M1 Students

## HOSPITAL TEACHING, ADVISING and MENTORING ROLES

### Didactic Teaching

Morning Report and Strategies for Leading Case-Based Resident Education

Annual lecture and discussion for chief pediatric residents, 2008-2018

Central Nervous System Tumors in Children and Adolescents, 2011-2018

2 lectures annually for Pediatric Resident Noon Conference Series

Topics in Biology of Pediatric Brain and Spinal Cord Tumors and Management of Children and Adolescents with Central Nervous System Tumors, 2011-2018

4 lectures annually for Pediatric Hematology-Oncology Fellow Lecture Series

Topics in Biology of Pediatric Brain and Spinal Cord Tumors and Management of Children and Adolescents with Central Nervous System Tumors, 2011-2018

12-15 lectures annually for Pediatric Neuro-Oncology Fellowship Lecture series

### Clinical Teaching

Bedside teaching of medical students, residents, nurse practitioners and fellows during inpatient service weeks and 96 ambulatory clinic sessions per year

Case based teaching at pediatric resident morning report 18-20 times per year

### Mentees

2011 –2013 Jeffrey Rubens MD, Resident Research Mentor

2012 –2015 Dustin Dillon MD, Resident Research Mentor

2012 –2013 Rebecca Loret De Mola DO, Neuro-Oncology Fellowship Research Mentor

2013 –2014 Natasha Pillay Smiley DO, Neuro-Oncology Fellowship Research Mentor

2014 –2015 Maggie Skrypek MD, Neuro-Oncology Fellowship Research Mentor

2015 –2017 Jessica Clymer MD, Hematology-Oncology Fellowship Research Mentor

2016 – Alicia Lenzen MD, Hematology-Oncology Fellowship Research and Faculty Mentor

2017 – 2018 Kathryn Laurie, MD, Hematology-Oncology Fellowship Research Mentor

2018 - Robyn Borsuk, MD, Hematology-Oncology Fellowship Research Mentor